Isomab Ltd
Dr Kishor Modha is currently the Vice President of Product Development at Isomab Ltd, focusing on the development of innovative humanized mAb for the treatment of peripheral arterial disease. With a background in microbiology and biotechnology, Dr. Modha has held various leadership positions in companies specializing in biotherapeutics, gene therapy, and veterinary diagnostics. Dr Kishor's expertise includes CMC product development, operations, and project management in the biopharmaceutical industry. Dr. Modha's educational background includes degrees in theology, microbiology, and biotechnology.
This person is not in any teams
Isomab Ltd
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.